Quoin Pharmaceuticals receives FDA fast track designation for QRX003
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St climbs as Mideast tensions ease, Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- SpaceX weighs Starlink mobile service to US consumers, FT reports
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
March 11, 2026 8:30 AM EDTFast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need
QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome
Fast Track Designation follows Pediatric Rare Disease and Orphan Drug Designation previously granted by the FDA and Orphan Drug Designation granted by the European Medicines Agency for QRX003 in Netherton Syndrome
ASHBURN, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on developing and... More
